JCR Pharmaceuticals Co., Ltd.

TSE:4552 Stock Report

Market Cap: JP¥68.7b

JCR Pharmaceuticals Valuation

Is 4552 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4552 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
JP¥936.59
Fair Value
39.8% undervalued intrinsic discount
7
Number of Analysts

Below Fair Value: 4552 (¥564) is trading below our estimate of fair value (¥936.59)

Significantly Below Fair Value: 4552 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4552?

Key metric: As 4552 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4552. This is calculated by dividing 4552's market cap by their current revenue.
What is 4552's PS Ratio?
PS Ratio1.9x
SalesJP¥35.26b
Market CapJP¥68.71b

Price to Sales Ratio vs Peers

How does 4552's PS Ratio compare to its peers?

The above table shows the PS ratio for 4552 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.4x
4569 KYORIN Pharmaceutical
0.7x-2.1%JP¥83.3b
4886 ASKA Pharmaceutical HoldingsLtd
0.9x4.1%JP¥55.3b
4534 Mochida Pharmaceutical
1.1xn/aJP¥117.3b
4565 Nxera Pharma
2.9x7.9%JP¥83.7b
4552 JCR Pharmaceuticals
1.9x3.3%JP¥68.7b

Price-To-Sales vs Peers: 4552 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (1.4x).

Price to Sales Ratio vs Industry

How does 4552's PS Ratio compare vs other companies in the JP Pharmaceuticals Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
4541 Nichi-Iko Pharmaceutical
0.1xn/aUS$185.57m
4539 Nippon Chemiphar
0.2xn/aUS$34.45m
No more companies available in this PS range
4552 1.9xIndustry Avg. 1.8xNo. of Companies6PS01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4552 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the JP Pharmaceuticals industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is 4552's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4552 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio1.9x

Price-To-Sales vs Fair Ratio: 4552 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4552 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥564.00
JP¥880.00
+56.0%
52.9%JP¥2,000.00JP¥610.00n/a7
Jan ’26JP¥607.00
JP¥880.00
+45.0%
52.9%JP¥2,000.00JP¥610.00n/a7
Dec ’25JP¥740.00
JP¥872.86
+18.0%
53.8%JP¥2,000.00JP¥600.00n/a7
Nov ’25JP¥679.00
JP¥877.14
+29.2%
54.4%JP¥2,000.00JP¥600.00n/a7
Oct ’25JP¥661.00
JP¥867.14
+31.2%
55.5%JP¥2,000.00JP¥600.00n/a7
Sep ’25JP¥626.00
JP¥852.86
+36.2%
57.3%JP¥2,000.00JP¥560.00n/a7
Aug ’25JP¥569.00
JP¥852.86
+49.9%
57.3%JP¥2,000.00JP¥560.00n/a7
Jul ’25JP¥614.00
JP¥851.43
+38.7%
57.5%JP¥2,000.00JP¥560.00n/a7
Jun ’25JP¥574.00
JP¥1,222.86
+113.0%
41.3%JP¥2,000.00JP¥560.00n/a7
May ’25JP¥813.00
JP¥1,557.14
+91.5%
17.8%JP¥2,000.00JP¥1,200.00n/a7
Apr ’25JP¥840.00
JP¥1,657.14
+97.3%
28.6%JP¥2,700.00JP¥1,200.00n/a7
Mar ’25JP¥895.00
JP¥1,657.14
+85.2%
28.6%JP¥2,700.00JP¥1,200.00n/a7
Feb ’25JP¥1,062.00
JP¥1,657.14
+56.0%
28.6%JP¥2,700.00JP¥1,200.00n/a7
Jan ’25JP¥1,172.00
JP¥1,842.86
+57.2%
27.2%JP¥2,700.00JP¥1,200.00JP¥607.007
Dec ’24JP¥1,261.00
JP¥1,842.86
+46.1%
27.2%JP¥2,700.00JP¥1,200.00JP¥740.007
Nov ’24JP¥1,130.00
JP¥1,857.14
+64.3%
27.4%JP¥2,700.00JP¥1,200.00JP¥679.007
Oct ’24JP¥1,495.50
JP¥1,943.33
+29.9%
25.4%JP¥2,700.00JP¥1,300.00JP¥661.006
Sep ’24JP¥1,268.50
JP¥1,901.43
+49.9%
26.4%JP¥2,800.00JP¥1,300.00JP¥626.007
Aug ’24JP¥1,378.00
JP¥1,901.43
+38.0%
26.4%JP¥2,800.00JP¥1,300.00JP¥569.007
Jul ’24JP¥1,269.00
JP¥2,007.14
+58.2%
26.8%JP¥2,800.00JP¥1,300.00JP¥614.007
Jun ’24JP¥1,377.00
JP¥2,185.71
+58.7%
25.1%JP¥2,900.00JP¥1,300.00JP¥574.007
May ’24JP¥1,451.00
JP¥2,412.50
+66.3%
20.8%JP¥2,900.00JP¥1,300.00JP¥813.008
Apr ’24JP¥1,413.00
JP¥2,412.50
+70.7%
20.8%JP¥2,900.00JP¥1,300.00JP¥840.008
Mar ’24JP¥1,423.00
JP¥2,475.00
+73.9%
16.5%JP¥2,900.00JP¥1,700.00JP¥895.008
Feb ’24JP¥1,636.00
JP¥2,562.50
+56.6%
20.8%JP¥3,400.00JP¥1,700.00JP¥1,062.008
Jan ’24JP¥1,681.00
JP¥2,673.75
+59.1%
18.6%JP¥3,400.00JP¥1,700.00JP¥1,172.008
Analyst Price Target
Consensus Narrative from 7 Analysts
JP¥880.00
Fair Value
35.9% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 18:22
End of Day Share Price 2025/01/15 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JCR Pharmaceuticals Co., Ltd. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tatsuyuki AraiBofA Global Research
Hidemaru YamaguchiCitigroup Inc
Kazuaki HashiguchiDaiwa Securities Co. Ltd.